Zelluna ASA (7UM)

Overview

Ultimovacs ASA is a pioneering biotech firm grounded in Oslo, Norway, with a mission to innovate in the realm of immunotherapies targeting various cancers. Since its incorporation in 2011, Ultimovacs has been at the forefront of developing novel treatments, focusing on harnessing the body's immune system to fight cancer. Their work revolves around creating vaccines that can train the immune system to recognize and eliminate cancer cells, aiming to provide a universal solution in the battle against this complex disease.

Products and Services

• UV1 - Peptide-based Cancer Vaccine

Ultimovacs' flagship product, UV1, stands as a testament to their innovative approach towards cancer treatment. This peptide-based cancer vaccine is designed to elicit a strong and specific T cell response against telomerase, a universal cancer antigen found in over 85% of all cancers. By targeting telomerase, UV1 has the potential to be used across a wide array of cancer types, making it a versatile and groundbreaking approach in the field of oncology. The development of UV1 underpins Ultimovacs' commitment to improving patient outcomes and offering new hope in the fight against cancer.